melanoma

[Human Vaccines & Immunotherapeutics] Scientists review and discuss the available published and ongoing clinical trials to explore the scientific background behind immunotherapy in the neoadjuvant context.

[Journal of Neuroinflammation] Neuroinflammation is thought to be a cause of Alzheimer’s disease (AD), which is partly caused by inadequate mitophagy. As a receptor of mitophagy, the authors revealed the regulatory roles of optineurin (OPTN) on neuroinflammation in the pathogenesis of AD.

[Pediatric Blood & Cancer] Exposure to trametinib and azacitidine prevented development of trametinib resistance in NRAS-mutated human melanoma cells in vitro. Azacitidine acted synergistically with trametinib to inhibit the growth of trametinib-resistant melanoma cells.

[Biomedicine & Pharmacotherapy] Scientists investigated the in vitro cytotoxic effect of previously developed nanocapsules, nanoemulsion, and microemulsion based on bullfrog oil against human melanoma cells.

[Molecular Biology Reports] Researchers reported that berberine has important antiproliferative effects and may be alone or in adjunct therapy a promising candidate for melanoma treatment, a cancer with great incidence and high lethality.

[Ultimovacs ASA] Ultimovacs ASA announces that the US FDA has granted orphan drug designation for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma.